Treace Medical Concepts, Inc. revised revenue guidance for the year 2023. Treace is raising its full-year 2023 revenue guidance to $191 million to $197 million, which represents approximately 35% to 39% growth over the Company?s 2022 revenue. This compares to the prior full-year 2023 revenue guidance of $190 million to $196 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.95 USD | +19.00% | +42.69% | -53.33% |
05-08 | Top Midday Decliners | MT |
05-08 | UBS Adjusts Price Target on Treace Medical Concepts to $16 From $17, Maintains Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-53.33% | 310M | |
+73.63% | 12.43B | |
-18.62% | 8.09B | |
-0.90% | 6.12B | |
+14.66% | 5.59B | |
-14.69% | 5.47B | |
+39.93% | 5.23B | |
-16.51% | 4.1B | |
-27.62% | 2.65B | |
+1.36% | 1.99B |
- Stock Market
- Equities
- TMCI Stock
- News Treace Medical Concepts, Inc.
- Treace Medical Concepts, Inc. Revises Revenue Guidance for the Year 2023